Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: adalimumab vs mycophenolate mofetil in steroid-dependent non-infectious uveitis
2023-505112-38-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and non-infectious panuveitis (NIU) comparing Adalimumab with Mycophenolate mofetil (2 arms). Primary endpoint: Treatment failure rate at week 36. Planned start Oct 2023; status: authorised.
02
Drugs
adalimumabmycophenolate mofetil
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on 2023-505112-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505112-38-00.